Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVAN trial: bevacizumab vs ranibizumab in neovascular AMD
2007-001281-33Phase 3Completed
- Sponsor
- Belfast Health and Social Care Trust
- Start
- Nov 2007
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab and ranibizumab in exudative macular degeneration and Subretinal neovascularization (4 arms), sponsored by Belfast Health and Social Care Trust. Primary endpoint: Best-corrected visual acuity at 2 years. Started Nov 2007; status: completed.
02
Drugs
bevacizumabranibizumab
03
Conditions
exudative macular degenerationSubretinal neovascularization
Beyond the preview
Go deeper on 2007-001281-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001281-33.